duvF0: Therakos’s flagship system is used to treat symptoms associated with a common form of blood cancer in patients who have been unresponsive to prior treatments. Last year, it bought Questcor Pharmaceuticals for about $5.9 billion and Cadence Pharmaceuticals for about $1.3 billion. The Therakos acquisition fits with the INOMAX buy, Mallinckrodt executives said on a call with analysts. ����OA�2 ��$�S�D�q �]���Ȣd100 ���� ` V Up to Friday's close, Mallinckrodt's shares had risen 47 percent in the past 12 months, outperforming an 8 percent rise in the S&P 500 Index .SPX. %PDF-1.5 %���� 1170 0 obj <> endobj HY��3��V�g���XX@j��`� ���;S�4#� }��s�&��d`py��\B�U�~ 3t[ The Gores Group Completes the Acquisition of Therakos, Inc. from Ortho-Clinical Diagnostics, Inc. January 02, 2013 08:30 AM Eastern Standard Time LOS ANGELES--(BUSINESS WIRE)- … 1193 0 obj <>stream Devices based on Therakos’s technology are the world’s only approved fully integrated systems for extracorporeal photopheresis, or ECP, in which blood is treated with a photosensitizing agent and irradiated with light. Gores Group bought Therakos from Ortho-Clinical Diagnostics Inc, a former subsidiary of Johnson & Johnson JNJ.N, in 2012.

With this acquisition, Mallinckrodt will gain access to Therakos’ therapeutic platforms, including the Therakos CELLEX Photopheresis System, which are … h�b```��l�B ���� 1184 0 obj <>/Filter/FlateDecode/ID[<6D874CBDFF8E8746A0DFE5DBF54B8428>]/Index[1170 24]/Info 1169 0 R/Length 78/Prev 660443/Root 1171 0 R/Size 1194/Type/XRef/W[1 2 1]>>stream

agreed to buy immunotherapy company Therakos Inc in a $1.33 billion deal, its second major acquisition this year to bolster its presence in hospitals. 0
Mallinckrodt, spun off from Covidien Plc in 2013, has relied on acquisitions to fuel growth. All quotes delayed a minimum of 15 minutes. The Ikaria deal gave Mallinckrodt access to INOMAX, the only approved product to treat hypoxic respiratory failure in infants. endstream endobj startxref ���ڜY��yz���"��������J̙S?�O �a�(}�i愂|��%� The Therakos acquisition fits with the INOMAX buy, Mallinckrodt executives said on a call with analysts. Shares of Mallinckrodt, which makes generic and specialty drugs as well as medical imaging agents, were little changed in afternoon trading on Monday. Mallinckrodt plans to sell Therakos’s devices to hospitals already using INOMAX and expects to generate sales of $500 million or more annually.

Mallinckrodt’s purchase of Therakos from investment firm Gores Group adds to its line of products that cater to surgical pain management and respiratory therapies in neonatal intensive care units. 4 Transaction highlights Acquisition of Therakos for approximately $1.325 billion Expected to be accretive by no less than $0.10 per share to adjusted diluted fiscal 2016 earnings and increasingly accretive thereafter 1 With roughly 60% of revenue in U.S Gores Group bought Therakos from Ortho-Clinical Diagnostics Inc, a former subsidiary of Johnson & Johnson, Up to Friday's close, Mallinckrodt's shares had risen 47 percent in the past 12 months, outperforming an 8 percent rise in the S&P 500 Index. It said it expected the deal to add at least 10 cents per share to adjusted profit in 2016, assuming a close in late fiscal 2015 ending September.

Mallinckrodt will purchase Therakos from investment firm The Gores Group for $1.325 billion, the buyer and seller said today. Dublin-based Mallinckrodt said it would focus on selling more of Therakos’s devices in the United States, where it is approved only for a form of blood cancer. endstream endobj 1171 0 obj <>/Metadata 205 0 R/OCProperties<>/OCGs[1185 0 R]>>/Outlines 260 0 R/PageLayout/SinglePage/Pages 1166 0 R/StructTreeRoot 283 0 R/Type/Catalog>> endobj 1172 0 obj <>/ExtGState<>/Font<>/Properties<>/XObject<>>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>> endobj 1173 0 obj <>stream �l+N�9\��/��:g&3�{InK��{2>N�i\�5���D䁃��9�0ȗ�}:g�ׁk����

Mallinckrodt said in March it would buy privately held Ikaria Inc, a maker of a respiratory drug and its delivery system, for $2.3 billion. Barclays advised Mallinckrodt on the deal, while Jefferies was Therakos’s adviser. h��T�O�0�W��q~9�P�6�iDؘ���^�&Ub$��ww�M���JW;w�}�|w�Y�&D��T�*YFk9n�/�M�0Jp#X#&�HE������듅���}��nN���A���V���F�uk�|�i�����_�B z�R���5�ڍ~!�A����'9X���d�T3 ��_w�^5��3�)�7�6rs�b��sf�g�˕� ��Q�ŋ�,�2�W��Ø7�!�P�@��x�_t��&E�?�1tɔ/�X�eךŢ{y. Outside the United States, the device is also used to treat Crohn’s disease, among other applications. The Gores Group, based in Los Angeles, acquired Therakos from Ortho Clinical Diagnostics, a former unit of Johnson & Johnson, for an undisclosed amount in December 2012. See here for a complete list of exchanges and delays. Our Standards: The Thomson Reuters Trust Principles. %%EOF

Mallinckrodt will finance the acquisition with cash and debt. �;��+::�$cy�d 0�Ɏ�r� C:B �;�.���i~H� �؟��L�– The platform is used by academic medical centers, hospitals and treatment centers in more than 25 countries.
(This version of the story corrects to “blood” from “skin” cancer in second and sixth paragraphs), Reporting by Natalie Grover and Ankur Banerjee in Bengaluru; Editing by Sriraj Kalluvila, Savio D’Souza and Don Sebastian. h�bbd``b`N�/@D!�� "� �� (Reuters) - Drugmaker Mallinckrodt Plc MNK.N agreed to buy immunotherapy company Therakos Inc in a $1.33 billion deal, its second major acquisition this year to bolster its presence in hospitals. Mallinckrodt Completes Acquisition Of Therakos, Inc.-- Adds depth and durability to Mallinckrodt's Specialty Brands segment; further diversifies its portfolio with an innovative high-value, high-margin drug-device system used in hospitals and major medical centers in